Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Cancer Research & Development Regulation

Sharpless Wonders Why Cancer Success Doesn't Translate To Other Diseases

  • Analysis

Executive Summary

Acting US FDA commissioner also said he wants to be nominated to the permanent position.

You may also be interested in...



Giroir Becomes Acting US FDA Commissioner, Giving Agency Experienced Political Hand

Assistant HHS secretary for health has led policy development for several offices since his 2018 confirmation and also has industry and clinical experience.

Former FDA Commissioners Push For Sharpless Nomination, Confirmation

Five former US FDA leaders and many stakeholder groups say Acting Commissioner Norman Sharpless should be the next permanent commissioner.

Former Commissioners Push For Sharpless Nomination, Confirmation

Five former US FDA leaders and many stakeholder groups say Acting Commissioner Norman Sharpless should be the next permanent commissioner.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Related Companies

Tags:
Cancer Research & Development Regulation
Latest Headlines

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

See All
UsernamePublicRestriction

Register

PS125491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By